Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Fangliang Zhang

Genscript Biotech Corporation

Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

NTrans Technologies specializes in non-viral delivery platforms for cell and gene therapies. The company focuses on delivering therapies to specific cells and tissues by leveraging natural mechanisms for cellular uptake.

NTrans Technologies

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

GenScript Antibody Services

GenScript Discovery Biology Services

GenScript Protein Services

GenScript Peptide Services

GenScript Catalog Products

GenScript Gene Services

GenScript Synthetic Biology Services

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has over 5,000 employees globally, 33% holding master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 100 patents and over 270 patent applications. As of June 2022, GenScript's products and services have been cited by 74,700 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

GenScript

📩 GenScript would like to invite you to the 𝙂𝙚𝙣𝙎𝙘𝙧𝙞𝙥𝙩 𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙂𝙡𝙤𝙗𝙖𝙡 𝙁𝙤𝙧𝙪𝙢 2024 at the Grand Hyatt in San Francisco on January 10, 2024.
 
Join us in uniting global thought leaders dedicated to advancing cures that will impact the lives of countless patients. It is an exclusive event where insights converge, focusing on recent developments, technological breakthroughs, commercialization challenges, and regulatory trends.
 
We would be honored to have you as our guest 👏 ! Secure your complimentary pass today using code "GS2024" on our event registration page: https://lnkd.in/eB94K5fk.
 
Your active engagement is critical in shaping the future of cell and gene therapy. Let's make a difference together 🤝 !

#biotechnology #lifesciences #genetherapy #celltherapy #biotechindustry #GSforum2024 

We are thrilled to announce GenScript has been named a BioSpace 2024 Best Place to Work!

We are grateful for our incredible team members who make our workplace truly exceptional. 

Cheers to the shared passion and dedication that sets us apart!

#bestplacetowork #teamwork


#researchadvance The microbiome, consisting of diverse microorganism communities including viruses, bacteria, fungi and eukaryotes colonizing human body surfaces, has recently been identified as a contributor to inter-individual variation, through its person-specific signatures. 

A recent review explores recent advances in the application of microbiome data in precision medicine across a growing number of human diseases. 

In this paper, researchers discuss the challenges, limitations and prospects of analysing microbiome data for personalized patient care. Eran Elinav Suhaib K. Abdeen

Read now: https://lnkd.in/e5mJK5wP

#microbiome #microorganism #humandiseases #precisionmedicine #patientcare #biotech 

Looking for high-quality Anti-DYKDDDDK affinity resins with great binding capacity and purity? 

Try GenScript's anti-DYKDDDDK G1 affinity resin (L00432), trusted by real users for top-notch purification in different expression systems! Explore user reviews and order now for speedy delivery.

Check out more details: https://lnkd.in/eiZEs4Mr

#catalogproducts #topnotch #highquality #offthechart #affinityresin #GSproducts 

Scientists from the University of Virginia School of Medicine have targeted lipid oxidation in the chronic liver disease, Non-Alcoholic Fatty Liver Disease (NAFLD), with an AAV8 delivered antibody fragment (scFv-E06). 

Learn how this approach is performing preclinically, providing a new opportunity to manage a disease with a global prevalence of over 30% and no FDA approved drugs: https://lnkd.in/eKQYbQfS

#liverdisease #antibodies #genetherapy #geneengineering #geneediting

Metric
Company Name	Genscript Biotech Corporation	Hera BioLabs	NTrans Technologies	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	1.55K
MSH ID	COM:GENSCRIPT	COM:HERABIOLABS	COM:NTRANSTECHNOLOGIES	COM:XYNOMICPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Pharmaceuticals
Country	CN	US	NL	US
Stage		Venture Round	Venture Round	Series B
Employee Count	6.94K
Website	genscript.com	herabiolabs.com	ntranstechnologies.com	xynomicpharma.com
LinkedIn	genscript-corporation		ntrans-technologies
Founders

Metric
Market Cap	2.59B
Enterprise Value
Monthly Web Traffic		1.41K	128	1.52K
Web Traffic Growth		-0.46	-0.59	4.19
Valuation
Raised Capital		1.07M	1.60M

Metric
Revenue	839.53M
Revenue (LTM)
Revenue (NTM)
Gross Profit	409.55M
EBITDA	-356.32M
Operating Income	-415.79M
Net Income	-95.48M
EPS	-0.05
Diluted EPS	-0.05
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54
Operating Profit Margin	-0.34
EBITDA Margin	-0.42
Net Profit Margin	-0.11
Return on Equity	-0.07
Return on Assets	-0.03
Return on Capital Employed	-0.12

1548

COM:GENSCRIPT

GenScript Biotech Corporation

Last Close

10.18

25/11 08:08

Market Cap

20.17B

Beta: -

Volume Today

7.76M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.03
P/B Ratio	3.40
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.56
EV Multiple	-8.88

Metric
Days Sales Outstanding
Days Payables Outstanding	63.28
Days Inventory Outstanding	46.00
Operating Cycle	139.82
Cash Conversion Cycle	105.90
Asset Turnover	0.30

Metric
Operating Cash Flow	-286.91M
Free Cash Flow	-543.41M
Cash Flow to Debt	-0.02
Operating Cash Flow/Sales	-0.02
Free Cash Flow Yield	-0.09

Metric
Cash & Equivalents	1.45B
Accounts Receivable
Inventory	53.35M
Goodwill	1.36M
Debt to Capitalization	0.42
Debt to Assets	0.14
Current Ratio	3.23
Quick Ratio	4.65

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10
R&D to Revenue	0.62
SG&A to Revenue	0.29